Tactica sale
This article was originally published in The Rose Sheet
Executive Summary
Helen of Troy sells its 55% ownership interest in Tactica International depilatory business to brand's current operating management, company announces April 30. Firm had announced plans to evaluate "strategic alternatives" for Tactica in October (1"The Rose Sheet" Oct. 6, 2003, p. 7) In light of the sale, Helen of Troy is revising its fiscal Q4 (ended Feb. 29) and year-end guidance. Fourth quarter net income from core business activities is expected to be approximately $16 mil., with an $8.5 mil.-$9.5 mil. loss attributed to Tactica operations. Consolidated net earnings, which will be announced May 13, are anticipated to be $6.5 mil.-$7.5 mil. Helen of Troy forecasts full-year consolidated net earnings of $59.2 mil.-$60.2 mil. and net income from the core business of $71 mil., with Tactica recording a $10.8 mil.-$11.8 mil. loss...
You may also be interested in...
Helen Of Troy Exploring Options For Tactica Depilatory Business
Helen of Troy is "evaluating strategic alternatives" for its investment in Tactica, the firm's depilatory products business, Chairman, President and CEO Gerald Rubin announced during a second quarter sales and earnings presentation Oct. 2
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.